AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 3679620 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextromethorphan (60 mg single dose) - Resilar
Number of subjects: 10
Study 3679620 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextromethorphan (60 mg single dose) - Redol comp.
Number of subjects: 10
Study 3679620 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextromethorphan (60 mg single dose) - Extuson
Number of subjects: 10
Study 29845764 — intervention group
Group type: EXPERIMENTAL
Intervention: LE-tablet computer use
Number of subjects: 9
Study 29845764 — intervention group
Group type: COMPARATOR
Intervention: Printed materials
Number of subjects: 9
Study 27435437 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydromorphone/naloxone (4:1 ratio)
Number of subjects: 12
Study 27435437 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydromorphone/naloxone (2:1 ratio)
Number of subjects: 12
Study 27435437 — intervention group
Group type: COMPARATOR
Intervention: Hydromorphone/naloxone placebo
Number of subjects: 12
Study 27435437 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydromorphone/naloxone (6:1 ratio)
Number of subjects: 12
Study 27435437 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydromorphone/naloxone (8:1 ratio)
Number of subjects: 12
Study 25194409 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone (30 mg/d)
Number of subjects: 62
Study 25194409 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study 24199672 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based cognitive behavioural treatment (ICBT) supported by short face-to-face consultations (MoodGYM)
Number of subjects: 14
Study 21387017 — intervention group
Group type: EXPERIMENTAL
Intervention: Second-order (contrast-based) visual motion stimuli
Number of subjects: 0
Study 21387017 — intervention group
Group type: COMPARATOR
Intervention: First-order (luminance-based) motion stimuli
Number of subjects: 0
Study 18310180 — intervention group
Group type: EXPERIMENTAL
Intervention: Repetition of sexual communication with parents
Number of subjects: 312
Study 18310180 — intervention group
Group type: EXPERIMENTAL
Intervention: Breadth of sexual communication with parents
Number of subjects: 312
Study 16969350 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery followed by adjuvant chemotherapy (UFT 400 mg day-1 for 1 year) in stage I patients (group B)
Number of subjects: 267
Study 16969350 — intervention group
Group type: COMPARATOR
Intervention: Surgery alone in stage I patients (group A)
Number of subjects: 267
Study 16969350 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery followed by chemotherapy (cisplatin and vindesine followed by UFT) in stage II or IIIA patients (group D)
Number of subjects: 267
Study 16969350 — intervention group
Group type: COMPARATOR
Intervention: Surgery alone in stage II or IIIA patients (group C)
Number of subjects: 267
Study 14551895 — intervention group
Group type: EXPERIMENTAL
Intervention: DNA ME-TRAP
Number of subjects: 0
Study 14551895 — intervention group
Group type: EXPERIMENTAL
Intervention: MVA ME-TRAP
Number of subjects: 0
Study 14551895 — intervention group
Group type: EXPERIMENTAL
Intervention: MVA ME-TRAP with prior DNA ME-TRAP immunization
Number of subjects: 0
Study 10992834 — intervention group
Group type: EXPERIMENTAL
Intervention: Succinylcholine (1 mg kg‐1)
Number of subjects: 0
Study 10992834 — intervention group
Group type: COMPARATOR
Intervention: Rocuronium (0.6 mg kg‐1)
Number of subjects: 0
Study 10992834 — intervention group
Group type: COMPARATOR
Intervention: Rocuronium (0.9 mg kg‐1)
Number of subjects: 0
Study 8804380 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepatitis A vaccine
Number of subjects: 0
Study 8804380 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepatitis B vaccine
Number of subjects: 0
Study 8804380 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepatitis C vaccine
Number of subjects: 0
Study 1607435 — intervention group
Group type: COMPARATOR
Intervention: Placebo dentifrice (0 ppm F)
Number of subjects: 19
Study 1607435 — intervention group
Group type: EXPERIMENTAL
Intervention: 250-ppm-F dentifrice
Number of subjects: 19
Study 1607435 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000-ppm-F dentifrice
Number of subjects: 19
Study 3484960 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose methotrexate with leucovorin calcium rescue (23 patients)
Number of subjects: 42
Study 3484960 — intervention group
Group type: COMPARATOR
Intervention: No chemotherapy (19 patients)
Number of subjects: 42
Study 29615061 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple periods of outdoor free-play (3 separate periods, each at least 15 min, from 9 am to 3 pm)
Number of subjects: 439
Study 29615061 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple periods of outdoor free-play
Number of subjects: 439
Study 29615061 — intervention group
Group type: COMPARATOR
Intervention: Usual single continuous period of outdoor free-play
Number of subjects: 439
Study 27479219 — intervention group
Group type: EXPERIMENTAL
Intervention: Slackline training (6 weeks)
Number of subjects: 28
Study 27479219 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 28
Study 27479219 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjects with improved slackline performance
Number of subjects: 28
Study 24982494 — intervention group
Group type: EXPERIMENTAL
Intervention: Referral Writer (RW) software program
Number of subjects: 0
Study 24982494 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard referral letters)
Number of subjects: 0
Study 22796761 — intervention group
Group type: EXPERIMENTAL
Intervention: Single subcutaneous injection of CMAB001 at doses of 0.5, 1.0, or 2.0 mg/kg
Number of subjects: 34
Study 22796761 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly subcutaneous injections of CMAB001 at a dose of 1.0 mg/kg for 7 weeks
Number of subjects: 34
Study 20163324 — intervention group
Group type: EXPERIMENTAL
Intervention: Albuterol/ipratropium bromide combination therapy
Number of subjects: 0
Study 20163324 — intervention group
Group type: COMPARATOR
Intervention: Albuterol
Number of subjects: 0
Study 20163324 — intervention group
Group type: COMPARATOR
Intervention: Ipratropium bromide
Number of subjects: 0
Study 19115911 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent hypoxic exposure (IHE) for 6 to 7 consecutive days (2-h ambient PO2=90 mmHg sedentary and 1-h ambient PO2=110 mmHg exercising at 80+/‐5% of maximum heart rate)
Number of subjects: 16
Study 19115911 — intervention group
Group type: COMPARATOR
Intervention: SHAM treatment for 6 to 7 consecutive days
Number of subjects: 16
Study 19115911 — intervention group
Group type: COMPARATOR
Intervention: Both IHE and SHAM groups
Number of subjects: 16
Study 18396244 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidepressant users (36.2% of participants, n = 50)
Number of subjects: 138
Study 18396244 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective serotonin reuptake inhibitors (SSRIs)
Number of subjects: 138
Study 18396244 — intervention group
Group type: EXPERIMENTAL
Intervention: Nortriptyline
Number of subjects: 138
Study 18396244 — intervention group
Group type: EXPERIMENTAL
Intervention: Other prescription medications
Number of subjects: 138
Study 15466607 — intervention group
Group type: EXPERIMENTAL
Intervention: Recall of distant poor team outcomes
Number of subjects: 0
Study 15466607 — intervention group
Group type: EXPERIMENTAL
Intervention: Good team outcomes
Number of subjects: 0
Study 15466607 — intervention group
Group type: EXPERIMENTAL
Intervention: Negotiation task measures obtained immediately or at a later time
Number of subjects: 0
Study 15466607 — intervention group
Group type: EXPERIMENTAL
Intervention: Team performance on an investment task
Number of subjects: 0
Study 11725980 — intervention group
Group type: EXPERIMENTAL
Intervention: Multipurpose solution with HPMC
Number of subjects: 147
Study 9227246 — intervention group
Group type: EXPERIMENTAL
Intervention: Contrast enhanced 3D MP‐RAGE
Number of subjects: 38
Study 9227246 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D CISS
Number of subjects: 38
Study 8384232 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% RA cream
Number of subjects: 0
Study 8384232 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.001% RA cream
Number of subjects: 0
Study 8384232 — intervention group
Group type: COMPARATOR
Intervention: 2% SDS in RA vehicle
Number of subjects: 0
Study 8384232 — intervention group
Group type: COMPARATOR
Intervention: Vehicle alone
Number of subjects: 0
Study 3609120 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 60 mg daily for 1 week
Number of subjects: 8
Study 3609120 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 31829133 — intervention group
Group type: EXPERIMENTAL
Intervention: Fall prevention decision tool implementation in general practice
Number of subjects: 560
Study 28347690 — intervention group
Group type: EXPERIMENTAL
Intervention: Nordic Walking Group (NWG)
Number of subjects: 42
Study 28347690 — intervention group
Group type: COMPARATOR
Intervention: Walking Group without poles (WG)
Number of subjects: 42
Study 26453120 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet and exercise lifestyle intervention (six visits to a dual qualified dietitian/exercise physiologist)
Number of subjects: 119
Study 26453120 — intervention group
Group type: COMPARATOR
Intervention: Attention control (scheduled telephone contact)
Number of subjects: 119
Study 26453120 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet and exercise lifestyle intervention
Number of subjects: 119
Study 23932463 — intervention group
Group type: EXPERIMENTAL
Intervention: Fimasartan 60 mg/d
Number of subjects: 92
Study 23932463 — intervention group
Group type: EXPERIMENTAL
Intervention: Fimasartan 120 mg/d
Number of subjects: 92
Study 23932463 — intervention group
Group type: COMPARATOR
Intervention: Valsartan 80 mg/d
Number of subjects: 92
Study 20974292 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based intervention for improving provider knowledge about strabismus and amblyopia (S/A) and preschool vision screening (PVS)
Number of subjects: 8590
Study 20974292 — intervention group
Group type: COMPARATOR
Intervention: Control group (blood pressure intervention)
Number of subjects: 8590
Study 19593972 — intervention group
Group type: EXPERIMENTAL
Intervention: Laserneedle acupuncture
Number of subjects: 64
Study 19593972 — intervention group
Group type: COMPARATOR
Intervention: Placebo (non-stimulation)
Number of subjects: 64
Study 16445332 — intervention group
Group type: EXPERIMENTAL
Intervention: Cued gait training with visual cues (initially 110% of uncued step length, later increased to 120%) for 4 weeks
Number of subjects: 1
Study 16445332 — intervention group
Group type: EXPERIMENTAL
Intervention: Cued gait training with visual cues
Number of subjects: 1
Study 16445332 — intervention group
Group type: COMPARATOR
Intervention: Uncued gait training
Number of subjects: 1
Study 14504090 — intervention group
Group type: EXPERIMENTAL
Intervention: Itraconazole (intravenous 200 mg daily, or oral solution 2.5 mg/kg 3 times daily)
Number of subjects: 197
Study 14504090 — intervention group
Group type: COMPARATOR
Intervention: Fluconazole (intravenous or oral, 400 mg daily)
Number of subjects: 197
Study 14504090 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide (CY) conditioning with itraconazole
Number of subjects: 197
Study 11342474 — intervention group
Group type: EXPERIMENTAL
Intervention: High concentrations of circulating IL-6 in patients with small aneurysms
Number of subjects: 485
Study 11342474 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-6 genotype (‐174 G‐‐>C polymorphism)
Number of subjects: 485
Study 11342474 — intervention group
Group type: EXPERIMENTAL
Intervention: GG genotype
Number of subjects: 485
Study 11342474 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-6 concentration in iliac arteries
Number of subjects: 485
Study 9412794 — intervention group
Group type: EXPERIMENTAL
Intervention: Flutamide 250 mg tid
Number of subjects: 104
Study 9412794 — intervention group
Group type: COMPARATOR
Intervention: Orchidectomy
Number of subjects: 104
Study 8433078 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholestyramine
Number of subjects: 120
Study 8433078 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin
Number of subjects: 120
Study 8433078 — intervention group
Group type: EXPERIMENTAL
Intervention: Apo E 3/3 phenotype
Number of subjects: 120
Study 8433078 — intervention group
Group type: EXPERIMENTAL
Intervention: Epsilon 2-allele
Number of subjects: 120
Study 8433078 — intervention group
Group type: COMPARATOR
Intervention: Apo E phenotype
Number of subjects: 120
Study 3625473 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer breakdown condition
Number of subjects: 62
Study 3625473 — intervention group
Group type: COMPARATOR
Intervention: Interruption condition
Number of subjects: 62
Study 3625473 — intervention group
Group type: COMPARATOR
Intervention: No-interruption condition
Number of subjects: 62
Study 30203762 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibandronate needle therapy
Number of subjects: 100
Study 30203762 — intervention group
Group type: COMPARATOR
Intervention: Zoledronic acid needle therapy
Number of subjects: 100
Study 27344665 — intervention group
Group type: COMPARATOR
Intervention: Piribedil (150–300 mg/day, three times daily)
Number of subjects: 0
Study 27344665 — intervention group
Group type: COMPARATOR
Intervention: Piribedil
Number of subjects: 0
Study 24684104 — intervention group
Group type: EXPERIMENTAL
Intervention: TEAS + GA
Number of subjects: 40
Study 24684104 — intervention group
Group type: COMPARATOR
Intervention: GA control
Number of subjects: 40
Study 22290206 — intervention group
Group type: EXPERIMENTAL
Intervention: Ziprasidone (80-160 mg/day)
Number of subjects: 80
Study 22290206 — intervention group
Group type: COMPARATOR
Intervention: Olanzapine (10-20 mg/day)
Number of subjects: 80
Study 20185361 — intervention group
Group type: EXPERIMENTAL
Intervention: Historical‐objective‐distribution based scale (Hi‐Ob‐Db)
Number of subjects: 100
Study 20185361 — intervention group
Group type: COMPARATOR
Intervention: Historical‐objective scale (Hi‐Ob)
Number of subjects: 100
Study 18397687 — intervention group
Group type: EXPERIMENTAL
Intervention: Serlift (50 mg)
Number of subjects: 24
Study 18397687 — intervention group
Group type: COMPARATOR
Intervention: Zoloft (50 mg)
Number of subjects: 24
Study 15653032 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel-eluting stent (PES)
Number of subjects: 202
Study 15653032 — intervention group
Group type: COMPARATOR
Intervention: Sirolimus-eluting stent (SES)
Number of subjects: 202
Study 12371727 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrafiltration at 20 ml/h-1/kg-1 (group 1, n = 146)
Number of subjects: 425
Study 12371727 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrafiltration at 35 ml/h-1/kg-1 (group 2, n = 139)
Number of subjects: 425
Study 12371727 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrafiltration at 45 ml/h-1/kg-1 (group 3, n = 140)
Number of subjects: 425
Study 9666415 — intervention group
Group type: COMPARATOR
Intervention: Leflunomide 25 mg once daily
Number of subjects: 402
Study 9666415 — intervention group
Group type: COMPARATOR
Intervention: Leflunomide 10 mg daily
Number of subjects: 402
Study 9666415 — intervention group
Group type: COMPARATOR
Intervention: Leflunomide 10 mg and 25 mg
Number of subjects: 402
Study 9666415 — intervention group
Group type: EXPERIMENTAL
Intervention: Leflunomide
Number of subjects: 402
Study 8033588 — intervention group
Group type: EXPERIMENTAL
Intervention: HIR-CAL grid-modified keratometer
Number of subjects: 45
Study 8033588 — intervention group
Group type: COMPARATOR
Intervention: Mengher-Tonge xeroscope
Number of subjects: 45
Study 2688186 — intervention group
Group type: EXPERIMENTAL
Intervention: HR capsules (1,200 mg/day)
Number of subjects: 101
Study 2688186 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 101
Study 31502736 — intervention group
Group type: EXPERIMENTAL
Intervention: Varenicline (Quit2Live trial)
Number of subjects: 870
Study 31502736 — intervention group
Group type: EXPERIMENTAL
Intervention: Varenicline (PNAT trial)
Number of subjects: 870
Study 29427081 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolcapone
Number of subjects: 0
Study 29427081 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromocriptine
Number of subjects: 0
Study 29427081 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 27711100 — intervention group
Group type: EXPERIMENTAL
Intervention: ALOKA end fire probe (size 74 mm)
Number of subjects: 114
Study 27711100 — intervention group
Group type: COMPARATOR
Intervention: B‐K Type 8818 probe (size 58 mm)
Number of subjects: 114
Study 24796978 — intervention group
Group type: EXPERIMENTAL
Intervention: Variable Resistance (VR) exercise during warm-up
Number of subjects: 16
Study 24796978 — intervention group
Group type: COMPARATOR
Intervention: Free Weight Resistance (FWR) exercise during warm-up
Number of subjects: 16
Study 24796978 — intervention group
Group type: EXPERIMENTAL
Intervention: Variable Resistance (VR) exercise
Number of subjects: 16
Study 23033982 — intervention group
Group type: EXPERIMENTAL
Intervention: aVQ (abnobaVISCUM(®) Quercus) injected subcutaneously three times per week from postoperative day 7 to week 24
Number of subjects: 32
Study 23033982 — intervention group
Group type: COMPARATOR
Intervention: No additional therapy (Control)
Number of subjects: 32
Study 20614484 — intervention group
Group type: EXPERIMENTAL
Intervention: EUS followed by ERCP under conscious sedation
Number of subjects: 54
Study 20614484 — intervention group
Group type: COMPARATOR
Intervention: EUS only (Control Group B)
Number of subjects: 54
Study 20614484 — intervention group
Group type: COMPARATOR
Intervention: ERCP only (Control Group C)
Number of subjects: 54
Study 18979342 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrical stimulation of the medial gastrocnemius muscle after acute passive stretching
Number of subjects: 12
Study 15837249 — intervention group
Group type: EXPERIMENTAL
Intervention: TAXUS stent
Number of subjects: 170
Study 15837249 — intervention group
Group type: COMPARATOR
Intervention: Control (bare-metal EXPRESS stent)
Number of subjects: 170
Study 12457672 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical anesthesia
Number of subjects: 107
Study 12457672 — intervention group
Group type: COMPARATOR
Intervention: Retrobulbar anesthesia
Number of subjects: 107
Study 12457672 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall incidence of PONV
Number of subjects: 107
Study 12457672 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical and retrobulbar anesthesia
Number of subjects: 107
Study 10845347 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of social support (appraisal, belonging, tangible)
Number of subjects: 103
Study 10845347 — intervention group
Group type: EXPERIMENTAL
Intervention: Interpersonal Support Evaluation List (quantitative support and esteem subscale)
Number of subjects: 103
Study 10845347 — intervention group
Group type: EXPERIMENTAL
Intervention: Measures of qualitative and quantitative social support
Number of subjects: 103
Study 8731496 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate aerobic exercise
Number of subjects: 60
Study 8731496 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive relaxation
Number of subjects: 60
Study 8731496 — intervention group
Group type: COMPARATOR
Intervention: Placebo group (group discussion)
Number of subjects: 60
Study 8731496 — intervention group
Group type: COMPARATOR
Intervention: Nonintervention control group
Number of subjects: 60
Study 1564703 — intervention group
Group type: EXPERIMENTAL
Intervention: Early luteal phase progesterone supplementation (group B)
Number of subjects: 72
Study 1564703 — intervention group
Group type: COMPARATOR
Intervention: Standard protocol progesterone supplementation after embryo transfer (group C)
Number of subjects: 72
Study 1564703 — intervention group
Group type: COMPARATOR
Intervention: Higher progesterone levels from early luteal phase through embryo transfer (group A)
Number of subjects: 72
Study 3901934 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral rehydration therapy (high sodium isotonic fluid at 40 ml/kg per hour during rehydration phase, low sodium isotonic fluid during maintenance phase)
Number of subjects: 470
Study 3901934 — intervention group
Group type: COMPARATOR
Intervention: Intravenous fluid therapy
Number of subjects: 470
Study 31699150 — intervention group
Group type: EXPERIMENTAL
Intervention: Apatinib (500 mg, p.o. q.d.) plus gefitinib (250 mg, p.o. q.d.)
Number of subjects: 310
Study 31699150 — intervention group
Group type: COMPARATOR
Intervention: Gefitinib plus placebo
Number of subjects: 310
Study 29897440 — intervention group
Group type: EXPERIMENTAL
Intervention: Annual mass azithromycin distribution
Number of subjects: 240
Study 29897440 — intervention group
Group type: COMPARATOR
Intervention: Biannual mass azithromycin distribution
Number of subjects: 240
Study 27362585 — intervention group
Group type: EXPERIMENTAL
Intervention: Arterial spin labelling (ASL) MRI
Number of subjects: 41
Study 25293478 — intervention group
Group type: EXPERIMENTAL
Intervention: Etomidate induction (group E)
Number of subjects: 60
Study 25293478 — intervention group
Group type: COMPARATOR
Intervention: Sevoflurane induction (group S)
Number of subjects: 60
Study 22323414 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term T1D group
Number of subjects: 16
Study 20137094 — intervention group
Group type: EXPERIMENTAL
Intervention: MIS-TKA (Minimal Invasion Surgery)
Number of subjects: 62
Study 20137094 — intervention group
Group type: COMPARATOR
Intervention: Standard TKA
Number of subjects: 62
Study 17671066 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolmitriptan nasal spray (5 mg)
Number of subjects: 248
Study 17671066 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 248
Study 15616064 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenosine triphosphate 0.1 mg.kg(‐1).min(‐1)
Number of subjects: 29
Study 15616064 — intervention group
Group type: COMPARATOR
Intervention: 0.9% NaCl (Control)
Number of subjects: 29
Study 11314774 — intervention group
Group type: EXPERIMENTAL
Intervention: Selegiline
Number of subjects: 9
Study 11314774 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 11314774 — intervention group
Group type: EXPERIMENTAL
Intervention: Selegiline (after reinstitution)
Number of subjects: 9
Study 9150864 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3% ciprofloxacin
Number of subjects: 30
Study 9150864 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3% ofloxacin
Number of subjects: 30
Study 9150864 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3% tobramycin
Number of subjects: 30
Study 7951338 — intervention group
Group type: EXPERIMENTAL
Intervention: Local radiotherapy of 18-20 Gy to the testis
Number of subjects: 1810